Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode (APPRAISE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04203056 |
|
Recruitment Status :
Terminated
(Withdraw of financial support by industry collaborator)
First Posted : December 18, 2019
Last Update Posted : October 12, 2022
|
Sponsor:
University of California, Los Angeles
Collaborator:
Alkermes, Inc.
Information provided by (Responsible Party):
Kenneth L. Subotnik, PhD, University of California, Los Angeles
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | October 1, 2022 |
| Actual Study Completion Date : | October 1, 2022 |